MediciNova Inc (MNOV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MediciNova Inc stock (MNOV) is currently trading at $1.45. MediciNova Inc PS ratio (Price-to-Sales) is 174.22. Analyst consensus price target for MNOV is $10.00. WallStSmart rates MNOV as Sell.
- MNOV PE ratio analysis and historical PE chart
- MNOV PS ratio (Price-to-Sales) history and trend
- MNOV intrinsic value — DCF, Graham Number, EPV models
- MNOV stock price prediction 2025 2026 2027 2028 2029 2030
- MNOV fair value vs current price
- MNOV insider transactions and insider buying
- Is MNOV undervalued or overvalued?
- MediciNova Inc financial analysis — revenue, earnings, cash flow
- MNOV Piotroski F-Score and Altman Z-Score
- MNOV analyst price target and Smart Rating
MediciNova Inc
📊 No data available
Try selecting a different time range
Smart Analysis
MediciNova Inc (MNOV) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
MediciNova Inc (MNOV) Key Strengths (1)
Trading at 1.82x book value, attractively priced
Supporting Valuation Data
MediciNova Inc (MNOV) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Very expensive at 174.2x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
MediciNova Inc (MNOV) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.82) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (174.22) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -25.50%, Operating Margin at -2038.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -25.50% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MNOV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MNOV's Price-to-Sales ratio of 174.22x sits near its historical average of 168.69x (86th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 174.22x set in Mar 2026, and 7% above its historical low of 162.21x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for MediciNova Inc (MNOV) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
MediciNova Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Spending 413% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact MediciNova Inc.
Bottom Line
MediciNova Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(2 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:04:36 AM
About MediciNova Inc(MNOV)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.